Viral kinetics suggests a reconciliation of the disparate observations of the modulation of claudin-1 expression on cells exposed to hepatitis C virus

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Padmanabhan, Pranesh ^a   Dixit, Narendra M ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CELL RECEPTOR; CLAUDIN 1; VIRUS RECEPTOR; MEMBRANE PROTEIN;

ARTICLE; CELL GROWTH; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; INFECTION SENSITIVITY; MATHEMATICAL MODEL; PREDICTION; PROTEIN EXPRESSION; SUPERINFECTION; VIRAL PHENOMENA AND FUNCTIONS; VIRUS ENTRY; VIRUS KINETICS; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; HOST PATHOGEN INTERACTION; KINETICS; PHYSIOLOGY; TIGHT JUNCTION; VIROLOGY;

GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; KINETICS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; TIGHT JUNCTIONS; VIRUS INTERNALIZATION;

EID: 84860124731     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036107     Document Type: Article

References (45)

1. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, et al. (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21: 5017-5025.
2. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, et al. (1998) Binding of hepatitis C virus to CD81. Science 282: 938-941.
3. Cormier EG, Tsamis F, Kajumo F, Durso RJ, Gardner JP, et al. (2004) CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci U S A 101: 7270-7274.
4. Evans MJ, von Hahn T, Tscherne DM, Syder AJ, Panis M, et al. (2007) Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446: 801-805.
5. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, et al. (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457: 882-886.
6. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF, (2011) Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies. J Hepatol 54: 566-576.
7. Farquhar MJ, Hu K, Harris HJ, Davis C, Brimacombe CL, et al. (2012) Hepatitis C virus induces CD81 and claudin-1 endocytosis. J Virol 86: 4305-4316.
8. Harris HJ, Davis C, Mullins JGL, Hu K, Goodall M, et al. (2010) Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem 285: 21092-21102.
9. Harris HJ, Farquhar MJ, Mee CJ, Davis C, Reynolds GM, et al. (2008) CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 82: 5007-5020.
10. Krieger SE, Zeisel MB, Davis C, Thumann C, Harris HJ, et al. (2010) Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology 51: 1144-1157.
11. Fofana I, Krieger SE, Grunert F, Glauben S, Xiao F, et al. (2010) Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology 139: 953-964.
12. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, et al. (2011) EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 17: 589-595.
13. Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, et al. (2011) Neutralizing antibody resistant hepatitis C virus cell-to-cell transmission. J Virol 85: 596-605.
14. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, et al. (2008) Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47: 17-24.
15. Reynolds GM, Harris HJ, Jennings A, Hu K, Grove J, et al. (2008) Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 47: 418-427.
16. Liu S, Yang W, Shen L, Turner JR, Coyne CB, et al. (2009) Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol 83: 2011-2014.
17. Tscherne DM, Evans MJ, von Hahn T, Jones CT, Stamataki Z, et al. (2007) Superinfection exclusion in cells infected with hepatitis C virus. J Virol 81: 3693-3703.
18. Schaller T, Appel N, Koutsoudakis G, Kallis S, Lohmann V, et al. (2007) Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J Virol 81: 4591-4603.
19. Rong L, Dahari H, Ribeiro RM, Perelson AS, (2010) Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2: 30ra32.
20. Kellam P, Larder BA, (1995) Retroviral recombination can lead to linkage of reverse-transcriptase mutations that confer increased zidovudine resistance. J Virol 69: 669-674.
21. Moutouh L, Corbeil J, Richman DD, (1996) Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure. Proc Natl Acad Sci U S A 93: 6106-6111.
22. Dixit NM, (2008) Modelling HIV infection dynamics: The role of recombination in the development of drug resistance. Future HIV Ther 2: 375-388.
23. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, et al. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282: 103-107.
24. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, et al. (2001) Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha-2a. Gastroenterology 120: 1438-1447.
25. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S, (2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37: 1351-1358.
26. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS, (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432: 922-924.
27. Dahari H, Ribeiro RM, Perelson AS, (2007) Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 46: 16-21.
28. Colombatto P, Ciccorossi P, Maina AM, Civitano L, Oliveri F, et al. (2008) Early and accurate prediction of peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells. Clin Pharmacol Ther 84: 212-215.
29. Rong L, Perelson AS, (2010) Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol 30: 131-148.
30. Adiwijaya BS, Herrmann E, Hare B, Kieffer T, Lin C, et al. (2010) A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput Biol 6: e1000745.
31. Guedj J, Perelson AS, (2011) Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration. Hepatology 53: 1801-1808.
32. Hsu CS, Hsu SJ, Chen HC, Tseng TC, Liu CH, et al. (2011) Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc Natl Acad Sci U S A 108: 3719-3724.
33. DebRoy S, Kribs-Zaleta C, Mubayi A, Cardona-Melendez GM, Medina-Rios L, et al. (2010) Evaluating treatment of hepatitis C for hemolytic anemia management. Math Biosci 225: 141-155.
34. Krishnan SM, Dixit NM, (2011) Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol 7: e1001072.
35. Dahari H, Ribeiro RM, Rice CM, Perelson AS, (2007) Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol 81: 750-760.
36. Dahari H, Sainz B Jr, Perelson AS, Uprichard SL, (2009) Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J Virol 83: 6383-6390.
37. Padmanabhan P, Dixit NM, (2011) Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry. PLoS Comput Biol 7: e1002307.
38. Zhong J, Gastaminza P, Chung J, Stamataki Z, Isogawa M, et al. (2006) Persistent hepatitis C virus infection in vitro: coevolution of virus and host. J Virol 80: 11082-11093.
39. Walters KA, Syder AJ, Lederer SL, Diamond DL, Paeper B, et al. (2009) Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes. PLoS Pathog 5: e1000269.
40. Sainz B Jr, Chisari FV, (2006) Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol 80: 10253-10257.
41. Yu X, Sainz B Jr, Uprichard SL, (2009) Development of a cell-based hepatitis C virus infection fluorescent resonance energy transfer assay for high-throughput antiviral compound screening. Antimicrob Agents Chemother 53: 4311-4319.
42. Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, et al. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med 18: 281-285.
43. Kannan RP, Hensley LL, Evers LE, Lemon SM, McGivern DR, (2011) Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol 85: 7989-8001.
44. Sabahi A, Marsh KA, Dahari H, Corcoran P, Lamora JM, et al. (2010) The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology 407: 110-119.
45. Beauchemin CAA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, et al. (2008) Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol 254: 439-451.